Vaxart Inc (VXRT) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.50 (+5.46%), Market cap $0.15B, P/E ratio 3.94, 52-week low–high $0.30 ~ $0.80.
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervi
Financial statements, price targets, institutional (13F) holdings and related news for Vaxart Inc are updated in real time on BlackAll Trade.
Vaxart Inc trades at $0.50 (+5.46%). Real-time quotes and charts are available on BlackAll Trade.
Vaxart Inc has a market cap of about $0.15B. Its P/E ratio is 3.94.
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine pla